Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Arguedas M.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 477-479

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors' Reply

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 478-479

Adis International

Access to resources Recommend Favorite

Financial Impact of Two Different Ways of Evaluating Early Virological Response to Peginterferon- -2b Plus Ribavirin Therapy in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1

By Buti Maria  

PharmacoEconomics, Vol. 23, Iss. 10, 2005-01 ,pp. : 1043-1055

Adis International

Access to resources Recommend Favorite

Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response: A Decision Analysis Based on German Guidelines

By Siebert Uwe   Sroczynski Gaby   Aidelsburger Pamela  

PharmacoEconomics, Vol. 27, Iss. 4, 2009-06 ,pp. : 341-354

Adis International

Access to resources Recommend Favorite

Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C

By Yeh Frank   Gordon Fredric D  

Future Virology, Vol. 2, Iss. 6, 2007-11 ,pp. : 553-563

Future Medicine

Access to resources Recommend Favorite